ENTRY       D03940                      Drug
NAME        Eculizumab (USAN/INN);
            Eculizumab (genetical recombination) (JAN);
            Soliris (TN)
PRODUCT     SOLIRIS (Alexion Pharmaceuticals)
REMARK      Therapeutic category: 6399
            ATC code: L04AA25
            Product: D03940<JP/US>
EFFICACY    Immunosuppressant, Anti-complement C5 antibody
  DISEASE   Paroxysmal nocturnal hemoglobinuria [DS:H01053]
            Atypical hemolytic uremic syndrome [DS:H01434]
            Generalized myasthenia gravis (AChR antibody positive) [DS:H01594]
            Neuromyelitis optica spectrum disorder (anti-AQP4 antibody positive) [DS:H01491]
  TYPE      Monoclonal antibody
TARGET      C5 [HSA:727] [KO:K03994]
  PATHWAY   hsa04610(727)  Complement and coagulation cascades
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA25 Eculizumab
                  D03940  Eculizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Complement Inhibitors
                Eculizumab
                 D03940  Eculizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D03940  Eculizumab (USAN/INN); Eculizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                C5
                 D03940  Eculizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03940
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03940
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03940
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03940
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D03940
DBLINKS     CAS: 219685-50-4
            PubChem: 47205928
///
